PT3303384T - Moléculas de ligação neutralizantes anti-influenza e suas utilizações - Google Patents

Moléculas de ligação neutralizantes anti-influenza e suas utilizações

Info

Publication number
PT3303384T
PT3303384T PT16728534T PT16728534T PT3303384T PT 3303384 T PT3303384 T PT 3303384T PT 16728534 T PT16728534 T PT 16728534T PT 16728534 T PT16728534 T PT 16728534T PT 3303384 T PT3303384 T PT 3303384T
Authority
PT
Portugal
Prior art keywords
binding molecules
neutralizing anti
influenza binding
influenza
neutralizing
Prior art date
Application number
PT16728534T
Other languages
English (en)
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of PT3303384T publication Critical patent/PT3303384T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PT16728534T 2015-06-01 2016-05-31 Moléculas de ligação neutralizantes anti-influenza e suas utilizações PT3303384T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562169272P 2015-06-01 2015-06-01

Publications (1)

Publication Number Publication Date
PT3303384T true PT3303384T (pt) 2021-10-14

Family

ID=56118059

Family Applications (1)

Application Number Title Priority Date Filing Date
PT16728534T PT3303384T (pt) 2015-06-01 2016-05-31 Moléculas de ligação neutralizantes anti-influenza e suas utilizações

Country Status (21)

Country Link
US (4) US10442854B2 (pt)
EP (2) EP3960761A1 (pt)
JP (3) JP6867306B2 (pt)
CN (2) CN107667114B (pt)
AU (2) AU2016271323B2 (pt)
BR (1) BR112017025496A2 (pt)
CA (1) CA2987816C (pt)
CY (1) CY1125793T1 (pt)
DK (1) DK3303384T3 (pt)
ES (1) ES2894777T3 (pt)
HR (1) HRP20211510T1 (pt)
HU (1) HUE056407T2 (pt)
LT (1) LT3303384T (pt)
MX (2) MX389708B (pt)
PL (1) PL3303384T3 (pt)
PT (1) PT3303384T (pt)
RS (1) RS62446B1 (pt)
RU (1) RU2721706C2 (pt)
SI (1) SI3303384T1 (pt)
SM (1) SMT202100591T1 (pt)
WO (1) WO2016196470A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113667013B (zh) 2013-10-02 2024-04-09 免疫医疗有限责任公司 中和抗甲型流感抗体及其用途
CA2954780A1 (en) 2014-07-15 2016-01-21 Medimmune, Llc Neutralizing anti-influenza b antibodies and uses thereof
HUE056407T2 (hu) * 2015-06-01 2022-02-28 Medimmune Llc Neutralizáló influenzaellenes kötõmolekulák és alkalmazásaik
US20190015509A1 (en) 2016-01-13 2019-01-17 Medimmune, Llc Method of treating influenza a
CA3088194A1 (en) 2018-01-26 2019-08-01 Regeneron Pharmaceuticals, Inc. Human antibodies to influenza hemagglutinin
US20220298230A1 (en) * 2019-06-11 2022-09-22 The Rockefeller University Antibodies and methods for treatment of viral infections
CN114761428A (zh) 2019-10-28 2022-07-15 瑞泽恩制药公司 抗血凝素抗体及其使用方法
CN113121680B (zh) * 2021-04-12 2022-03-29 华南农业大学 一种抗h5亚型禽流感纳米抗体蛋白及其编码基因与应用
US20250243261A1 (en) * 2022-04-08 2025-07-31 Cz Biohub Sf, Llc Antibody compositions and optimization methods
CN116874606B (zh) * 2023-09-08 2023-11-24 益科思特(北京)医药科技发展有限公司 一种靶向trop2和cd3的双特异性抗体及其制备方法与应用

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5981216A (en) 1985-04-01 1999-11-09 Alusuisse Holdings A.G. Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
SE9504046D0 (sv) 1995-11-14 1995-11-14 Pharmacia Ab Method of determining affinity and kinetic properties
WO1997044664A1 (en) 1996-05-23 1997-11-27 Unilever Plc Improvements in or relating to specific binding assays
WO1998057993A1 (en) 1997-06-19 1998-12-23 The Regents Of The University Of California Secretory immunoglobulin produced by single cells and methods for making and using same
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
AU1728800A (en) 1998-11-18 2000-06-05 Genentech Inc. Antibody variants with higher binding affinity compared to parent antibodies
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
WO2000059932A1 (fr) 1999-03-31 2000-10-12 Otsuka Pharmaceutical Co., Ltd. Peptides se liant a l'hemagglutinine du virus de la grippe
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
US8101553B1 (en) 2000-02-22 2012-01-24 Medical & Biological Laboratories Co., Ltd. Antibody library
US7029872B2 (en) 2000-06-28 2006-04-18 Glycofi, Inc Methods for producing modified glycoproteins
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
WO2004001007A2 (en) 2002-06-21 2003-12-31 Idec Pharmaceuticals Corporation Buffered formulations for concentrating antibodies and methods of use thereof
AU2003251809A1 (en) 2002-07-11 2004-02-02 The General Hospital Corporation Polynucleotide and polypeptide fat metabolism regulators and uses thereof
RU2366662C2 (ru) 2003-07-23 2009-09-10 Фуджирибайо Инк. Моноклональное антитело к вирусу типа а гриппа и устройство для иммунного анализа с использованием антитела
WO2005014038A1 (ja) 2003-08-11 2005-02-17 The Research Foundation For Microbial Diseases Of Osaka University 粘膜免疫誘導アジュバントを含む新規ワクチン
DE602005016683D1 (de) 2004-07-10 2009-10-29 Fox Chase Cancer Ct Genetisch modifizierte, menschliche, natürliche killerzellenlinien:
WO2006124269A2 (en) 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
JP5006330B2 (ja) 2005-10-21 2012-08-22 ノバルティス アーゲー Ｉｌ１３に対するヒト抗体および治療的使用
DK1974040T3 (da) 2006-01-17 2012-12-17 Synthon Biopharmaceuticals Bv Sammensætninger og fremgangsmåder til humanisering og optimering af N-glycanet i planter.
WO2007109742A2 (en) 2006-03-21 2007-09-27 Weaver David T Methods for humanizing antibodies and humanized antibodies made thereby
US7615220B2 (en) 2006-04-07 2009-11-10 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-18 receptor
JP2009537147A (ja) 2006-05-15 2009-10-29 シー レーン バイオテクノロジーズ， エルエルシー インフルエンザウイルスに対する中和抗体
EP2059532B1 (en) 2006-09-07 2012-12-26 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
CN101522716B (zh) 2006-10-02 2013-03-20 瑞泽恩制药公司 抗人il-4受体的高亲和力人抗体
AU2007325872B2 (en) 2006-11-08 2012-12-13 Macrogenics West, Inc. TES7 and antibodies that bind thereto
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
US8124092B2 (en) 2007-03-13 2012-02-28 Institute For Research In Biomedicine Antibodies against H5N1 strains of influenza A virus
EP1995309A1 (en) 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
ITTO20080398A1 (it) 2008-05-27 2009-11-28 Pomona Biotechnologies Llc Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1
BRPI0911699B8 (pt) 2008-07-25 2023-02-28 Inst Res Biomedicine vetor, célula, composição farmacêutica, uso de um anticorpo, ou fragmento de ligação a antígeno deste
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
US20120128684A1 (en) 2008-08-25 2012-05-24 Burnham Institute For Medical Research Conserved Hemagglutinin Epitope, Antibodies to the Epitope and Methods of Use
CA2742968C (en) 2008-11-07 2020-06-09 Fabrus Llc Combinatorial antibody libraries and uses thereof
CA2821492A1 (en) 2010-12-13 2012-06-21 The University Of Utah Research Foundation Vaccine antigens that direct immunity to conserved epitopes
WO2013007770A1 (en) * 2011-07-14 2013-01-17 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses
HUE044089T2 (hu) 2011-07-18 2019-09-30 Inst Res Biomedicine Neutralizáló anti-influenza A antitestek és alkalmazásaik
ES2953393T3 (es) 2011-09-20 2023-11-10 Icahn School Med Mount Sinai Vacunas contra el virus de la influenza y sus usos
US9441019B2 (en) 2011-09-23 2016-09-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Influenza hemagglutinin protein-based vaccines
WO2013086052A2 (en) * 2011-12-05 2013-06-13 Trellis Bioscience, Llc Antibodies useful in passive influenza immunization
CA2865594C (en) * 2012-03-08 2021-07-27 Crucell Holland B.V. Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
MA38176A1 (fr) 2012-11-13 2017-06-30 Genentech Inc Nouvel anticorps anti-hemagglutinine, utile pour le traitement, l'inhibition ou la prévention de l’infection virale a grippe a
KR20140118682A (ko) 2013-03-29 2014-10-08 (주)셀트리온 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물
RU2536956C1 (ru) * 2013-08-05 2014-12-27 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт пульмонологии Федерального медико-биологического агентства" Противовирусное однодоменное мини-антитело, нуклеотидная последовательность, экспрессирующий рекомбинантный вирусный вектор, фармацевтическая композиция и способ профилактики или терапии гриппа типа а
CN113667013B (zh) * 2013-10-02 2024-04-09 免疫医疗有限责任公司 中和抗甲型流感抗体及其用途
CA2954780A1 (en) 2014-07-15 2016-01-21 Medimmune, Llc Neutralizing anti-influenza b antibodies and uses thereof
HUE056407T2 (hu) * 2015-06-01 2022-02-28 Medimmune Llc Neutralizáló influenzaellenes kötõmolekulák és alkalmazásaik
US20190015509A1 (en) 2016-01-13 2019-01-17 Medimmune, Llc Method of treating influenza a
CA3015347A1 (en) 2016-02-24 2017-08-31 Visterra, Inc. Formulations of antibody molecules to influenza virus

Also Published As

Publication number Publication date
CN107667114A (zh) 2018-02-06
RU2721706C2 (ru) 2020-05-21
US20230112916A1 (en) 2023-04-13
US11524993B2 (en) 2022-12-13
EP3303384A1 (en) 2018-04-11
LT3303384T (lt) 2021-10-11
US20210079069A1 (en) 2021-03-18
US20180155413A1 (en) 2018-06-07
CA2987816A1 (en) 2016-12-08
MX389708B (es) 2025-03-20
CN113480640B (zh) 2024-07-30
JP2023078352A (ja) 2023-06-06
HUE056407T2 (hu) 2022-02-28
AU2016271323A1 (en) 2018-01-18
JP2018518475A (ja) 2018-07-12
JP6867306B2 (ja) 2021-04-28
US10882897B2 (en) 2021-01-05
PL3303384T3 (pl) 2022-01-03
EP3960761A1 (en) 2022-03-02
HK1250725A1 (zh) 2019-01-11
SI3303384T1 (sl) 2021-11-30
RS62446B1 (sr) 2021-11-30
US10442854B2 (en) 2019-10-15
CN107667114B (zh) 2021-07-02
HRP20211510T1 (hr) 2021-12-24
EP3303384B1 (en) 2021-08-25
HK1253092A1 (zh) 2019-06-06
CN113480640A (zh) 2021-10-08
RU2017145094A (ru) 2019-07-09
AU2022271473A1 (en) 2022-12-22
AU2016271323B2 (en) 2022-08-25
CA2987816C (en) 2024-02-20
US20200109187A1 (en) 2020-04-09
US11926657B2 (en) 2024-03-12
DK3303384T3 (da) 2021-10-18
JP2021112193A (ja) 2021-08-05
MX2022001220A (es) 2022-03-02
MX2017015189A (es) 2018-04-13
ES2894777T3 (es) 2022-02-15
WO2016196470A1 (en) 2016-12-08
CY1125793T1 (el) 2024-02-16
BR112017025496A2 (pt) 2018-08-07
SMT202100591T1 (it) 2021-11-12
RU2017145094A3 (pt) 2019-11-06

Similar Documents

Publication Publication Date Title
IL287848A (en) Multispecific antigen binding molecules and their uses
IL254223A (en) CD20 binding compounds and their uses
IL251891A0 (en) CD73-specific binding molecules and uses thereof
IL259585A (en) Antibody molecules for april and their uses
ZA201705300B (en) Binding molecules directed against influenza hemagglutinin and uses thereof
EP3331549A4 (en) Improved microbe-binding molecules and uses thereof
GB201615617D0 (en) Small molecules
GB201612520D0 (en) Binding molecules
GB201521858D0 (en) Small molecules
LT3303384T (lt) Neutralizuojančios surišančios molekulės prieš gripą ir jų naudojimas
GB201500463D0 (en) Therapeutic molecules
GB201500461D0 (en) Therapeutic molecules
GB201503812D0 (en) Antibody molecules and uses thereof
GB201702091D0 (en) Specific binding molecules
IL254241A0 (en) Etv2 and its uses
GB201706042D0 (en) Small molecules
GB201706043D0 (en) Small molecules
GB201508729D0 (en) Binding molecules
GB201600559D0 (en) Therapeutic molecules
HK1241931A1 (zh) Cd20結合分子及其用途